LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Fate Therapeutics Inc

Closed

SectorHealthcare

1.05 3.96

Overview

Share price change

24h

Current

Min

1.04

Max

1.11

Key metrics

By Trading Economics

Income

-4.5M

-52M

Sales

-1.2M

1.9M

EPS

-0.44

Profit margin

-2,803.925

Employees

181

EBITDA

10M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+381.31% upside

Dividends

By Dow Jones

Next Earnings

11 sie 2025

Market Stats

By TradingEconomics

Market Cap

5.3M

123M

Previous open

-2.91

Previous close

1.05

News Sentiment

By Acuity

40%

60%

121 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 maj 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 maj 2025, 23:40 UTC

Market Talk

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 maj 2025, 18:00 UTC

Earnings

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 maj 2025, 17:01 UTC

Top News

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 maj 2025, 16:20 UTC

Earnings

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 maj 2025, 12:09 UTC

Top News

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 maj 2025, 17:15 UTC

Top News

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 maj 2025, 09:30 UTC

Top News
Earnings

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 maj 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 maj 2025, 08:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 maj 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 maj 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16 maj 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 maj 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 maj 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 maj 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 maj 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 maj 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 maj 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 maj 2025, 20:55 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 maj 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 maj 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 maj 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 maj 2025, 20:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 maj 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 maj 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 maj 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 maj 2025, 20:15 UTC

Earnings

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 maj 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: William K. Daniel Joins Board

16 maj 2025, 20:10 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: Strategic Investment by KKR Completed

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

381.31% upside

12 Months Forecast

Average 5.15 USD  381.31%

High 12 USD

Low 2 USD

Based on 13 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

121 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.